Will Moderna’s Strong Q1 Help Its Beaten Down Stock?
- Friday, May 6, 2022, 7:10
- Market
- Add a comment
Total revenues rose to around $6.07 billion, with earnings per share standing at $8.58, marking a three-fold increase from the year-ago period when the company just started ramping up its vaccine sales.
About the Author
admin123 has written 23527 stories on this site.
